Madhu Kumar
Stock Analyst at Goldman Sachs
(2.90)
# 1,715
Out of 4,981 analysts
151
Total ratings
56.86%
Success rate
20.27%
Average return
Main Sectors:
Stocks Rated by Madhu Kumar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $162 → $185 | $126.16 | +46.64% | 8 | Aug 29, 2025 | |
| FULC Fulcrum Therapeutics | Maintains: Neutral | $5 → $6 | $7.02 | -14.53% | 8 | Jan 26, 2024 | |
| INFA Informatica | Maintains: Neutral | $23 → $26 | $24.77 | +4.97% | 5 | Dec 7, 2023 | |
| UTZ Utz Brands | Maintains: Neutral | $19 → $17 | $12.95 | +31.27% | 2 | Nov 10, 2023 | |
| ALEC Alector | Initiates: Sell | $4 | $2.75 | +45.45% | 4 | Sep 25, 2023 | |
| KRYS Krystal Biotech | Maintains: Buy | $135 → $155 | $143.68 | +7.88% | 13 | May 22, 2023 | |
| CYTK Cytokinetics | Maintains: Buy | $48 → $53 | $51.13 | +3.66% | 4 | May 5, 2023 | |
| DSGN Design Therapeutics | Upgrades: Neutral | n/a | $6.09 | - | 3 | May 4, 2023 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $65 → $73 | $29.72 | +145.63% | 10 | May 3, 2023 | |
| APLS Apellis Pharmaceuticals | Maintains: Buy | $124 → $141 | $24.85 | +467.40% | 9 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $34 | $15.55 | +118.65% | 6 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $20 → $6 | $2.27 | +164.32% | 8 | Dec 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $14 | $17.32 | -19.17% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $21 | $9.41 | +123.17% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $14.24 | -64.89% | 3 | Aug 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $10 → $8 | $2.69 | +197.40% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $111 → $89 | $7.74 | +1,049.87% | 4 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $580 → $120 | $7.00 | +1,614.29% | 1 | Jan 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $10 | $0.42 | +2,277.56% | 1 | Aug 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $85 | $11.42 | +644.31% | 7 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $23 → $39 | $2.89 | +1,249.48% | 3 | Mar 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $58 → $57 | $16.49 | +245.77% | 3 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.46 | - | 15 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $900 | $1.54 | +58,190.16% | 1 | Apr 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $17 → $20 | $5.00 | +300.00% | 2 | Mar 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $0.79 | +12,574.27% | 5 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $31.67 | +10.51% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $60 | $0.29 | +20,412.82% | 1 | Feb 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $40 | $13.35 | +199.63% | 2 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $504 | $21.80 | +2,212.46% | 3 | Oct 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $210 → $230 | $465.89 | -50.63% | 2 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $150 → $1,125 | $12.59 | +8,835.66% | 2 | Feb 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $1.26 | +3,074.60% | 1 | Feb 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $22 | $32.16 | -33.15% | 1 | Dec 1, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $56.26 | -58.23% | 1 | Mar 28, 2017 |
Jazz Pharmaceuticals
Aug 29, 2025
Maintains: Buy
Price Target: $162 → $185
Current: $126.16
Upside: +46.64%
Fulcrum Therapeutics
Jan 26, 2024
Maintains: Neutral
Price Target: $5 → $6
Current: $7.02
Upside: -14.53%
Informatica
Dec 7, 2023
Maintains: Neutral
Price Target: $23 → $26
Current: $24.77
Upside: +4.97%
Utz Brands
Nov 10, 2023
Maintains: Neutral
Price Target: $19 → $17
Current: $12.95
Upside: +31.27%
Alector
Sep 25, 2023
Initiates: Sell
Price Target: $4
Current: $2.75
Upside: +45.45%
Krystal Biotech
May 22, 2023
Maintains: Buy
Price Target: $135 → $155
Current: $143.68
Upside: +7.88%
Cytokinetics
May 5, 2023
Maintains: Buy
Price Target: $48 → $53
Current: $51.13
Upside: +3.66%
Design Therapeutics
May 4, 2023
Upgrades: Neutral
Price Target: n/a
Current: $6.09
Upside: -
Arrowhead Pharmaceuticals
May 3, 2023
Maintains: Buy
Price Target: $65 → $73
Current: $29.72
Upside: +145.63%
Apellis Pharmaceuticals
Apr 14, 2023
Maintains: Buy
Price Target: $124 → $141
Current: $24.85
Upside: +467.40%
Mar 1, 2023
Maintains: Buy
Price Target: $39 → $34
Current: $15.55
Upside: +118.65%
Dec 9, 2022
Downgrades: Neutral
Price Target: $20 → $6
Current: $2.27
Upside: +164.32%
Nov 10, 2022
Maintains: Sell
Price Target: $8 → $14
Current: $17.32
Upside: -19.17%
Nov 4, 2022
Maintains: Buy
Price Target: $24 → $21
Current: $9.41
Upside: +123.17%
Aug 25, 2022
Downgrades: Sell
Price Target: $5
Current: $14.24
Upside: -64.89%
May 24, 2022
Maintains: Sell
Price Target: $10 → $8
Current: $2.69
Upside: +197.40%
May 24, 2022
Maintains: Buy
Price Target: $111 → $89
Current: $7.74
Upside: +1,049.87%
Jan 19, 2022
Downgrades: Neutral
Price Target: $580 → $120
Current: $7.00
Upside: +1,614.29%
Aug 27, 2021
Downgrades: Sell
Price Target: $10
Current: $0.42
Upside: +2,277.56%
Jun 23, 2021
Maintains: Neutral
Price Target: $60 → $85
Current: $11.42
Upside: +644.31%
Mar 16, 2021
Upgrades: Outperform
Price Target: $23 → $39
Current: $2.89
Upside: +1,249.48%
Jul 31, 2020
Upgrades: Outperform
Price Target: $58 → $57
Current: $16.49
Upside: +245.77%
Jul 24, 2020
Downgrades: Neutral
Price Target: n/a
Current: $4.46
Upside: -
Apr 21, 2020
Initiates: Outperform
Price Target: $900
Current: $1.54
Upside: +58,190.16%
Mar 27, 2020
Maintains: Underperform
Price Target: $17 → $20
Current: $5.00
Upside: +300.00%
Mar 13, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $0.79
Upside: +12,574.27%
Mar 12, 2020
Initiates: Outperform
Price Target: $35
Current: $31.67
Upside: +10.51%
Feb 11, 2020
Initiates: Outperform
Price Target: $60
Current: $0.29
Upside: +20,412.82%
Sep 24, 2019
Maintains: Buy
Price Target: $58 → $40
Current: $13.35
Upside: +199.63%
Oct 8, 2018
Upgrades: Buy
Price Target: $504
Current: $21.80
Upside: +2,212.46%
Aug 13, 2018
Maintains: Buy
Price Target: $210 → $230
Current: $465.89
Upside: -50.63%
Feb 9, 2018
Maintains: Buy
Price Target: $150 → $1,125
Current: $12.59
Upside: +8,835.66%
Feb 8, 2018
Initiates: Buy
Price Target: $40
Current: $1.26
Upside: +3,074.60%
Dec 1, 2017
Reinstates: Buy
Price Target: $22
Current: $32.16
Upside: -33.15%
Mar 28, 2017
Initiates: Buy
Price Target: $24
Current: $56.26
Upside: -58.23%